The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer

Pereira, Augusto; Pérez-Medina, Tirso; Magrina, Javier F.; Magtibay, Paul M.; Rodríguez-Tapia, Ana; Pérez-Milán, Federico; Ortiz-Quintana, Luís

doi:10.1016/j.suronc.2013.10.005

Cited by 11 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This confusing result could be only resolved when more studies were conducted to confirm clinical values of the CTCs in ovarian cancer. On the other hand, ovarian cancer grows and recurs mainly in direct dissemination in the abdominal cavity [ 42 ]. Lymph nodes metastasis occur only when cancer cells invade lymphatic vessels while CTCs/DTCs occur only when cancer cells invade blood vessels.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis

2015

View full text Add to dashboard Cite

Recent studies have shown diagnostic and prognostic values of circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) in various cancers, including ovarian cancer. We aimed to evaluate the association of CTCs and/or DTCs with the clinical outcomes of ovarian cancer. Clinical studies of CTCs/DTCs of ovarian cancer were included for systematic review and meta-analysis. A total of 236 studies were screened but only 16 qualified studies with 1623 subjects were included. Odds ratio (OR) showed CTCs/DTCs were not significantly associated with serous carcinoma (OR = 0.71 [0.49, 1.05]), lymph node metastasis (OR 1.14 [0.67, 1.93]), and residual disease (OR 1.45 [0.90, 2.34]); but significantly associated with advanced tumor staging (OR = 1.90 [1.02, 3.56]). The overall pooled hazard ratio (HR) of CTCs/DTCs on OS and PFS/DFS was 1.94 [1.56– 2.40] and 1.99 [1.59–2.50], respectively. Subgroup analyses revealed that CTCs were significantly associated OS (HR 1.97 [1.50-2.58]) and PFS/DFS (HR 2.52 [1.83-3.48]), while DTCs was significantly associated OS (HR 1.89 [1.33, 2.68]) and PFS/DFS (HR 1.60 [1.17, 2.19]). Meta-analysis showed strong relationship of CTCs/DTCs with advanced staging, treatment response and poor prognosis in patients with ovarian cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-015-0168-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis

2015

View full text Add to dashboard Cite

show abstract

“…Not surprisingly, the degree of LN involvement strongly influences clinical care decisions: for example, stage I patients with metastatic LNs get upstaged to stage IIIC (11,12). Thus, the accurate evaluation of the site and status of LN involvement in addition to peritoneal carcinomatosis is critical for the treatment planning of HGSOC patients (13). …”

mentioning

confidence: 99%

Preclinical ⁸⁹Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis

et al. 2016

View full text Add to dashboard Cite

The elevation of cancer antigen 125 (CA125) levels in the serum of asymptomatic patients precedes the radiologic detection of high-grade serous ovarian cancer by at least 2 mo and the final clinical diagnosis by 5 mo. PET imaging of CA125 expression by ovarian cancer cells may enhance the evaluation of the extent of disease and provide a roadmap to surgery as well as detect recurrence and metastases. Methods 89Zr-labeled mAb-B43.13 was synthesized to target CA125 and evaluated via PET imaging and biodistribution studies in mice bearing OVCAR3 human ovarian adenocarcinoma xenografts. Ex vivo analysis of tumors and lymph nodes was performed via autoradiography, histopathology, and immunohistochemistry. Results PET imaging using 89Zr-DFO-mAb-B43.13 (DFO is desferrioxamine) clearly delineated CA125-positive OVCAR3 xenografts as early as 24 h after the administration of the radioimmunoconjugate. Biodistribution studies revealed accretion of 89Zr-DFO-mAb-B43.13 in the OVCAR3 tumors, ultimately reaching 22.3 ± 6.3 percentage injected dose per gram (%ID/g) at 72 h after injection. Most interestingly, activity concentrations greater than 50 %ID/g were observed in the ipsilateral lymph nodes of the xenograft-bearingmice. Histopathologic analysis of the immuno-PET–positive lymph nodes revealed the presence of grossly metastasized ovarian cancer cells within the lymphoid tissues. In control experiments, only low-level, non-specific uptake of 89Zr-labeled isotype IgG was observed in OVCAR3 tumors; similarly, low-activity concentrations of 89Zr-DFO-mAb-B43.13 accumulated in CA125-negative SKOV3 tumors. Conclusion Immuno-PET with 89Zr-labeled mAb-B43.13 is a potential strategy for the noninvasive delineation of extent of disease and may add value in treatment planning and treatment monitoring of high-grade serous ovarian cancer.

show abstract

“…Extra-abdominal disease was considered an independent prognostic factor for survival. 8,12 In conclusion, the current 2014 FIGO staging system for ovarian cancer successfully correlates survival, the anatomical location of peritoneal metastases, and the location of extra-abdominal lymph node metastases. Prospective studies are needed to evaluate the impact of upper abdominal organ involvement on survival.…”

Section: Discussionmentioning

confidence: 84%

“…The demographics and survival analyses of patients with distant lymph node metastases have been reported elsewhere. 8 The survival data for 2014 FIGO stage IVare shown in Table 2.…”

Section: Stage IVmentioning

confidence: 99%

International Federation of Gynecology and Obstetrics Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Estimation of Survival in Patients With Node-Positive Epithelial Ovarian Cancer

Pereira

Pérez-Medina

Magrina

et al. 2015

Int J Gynecol Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer

Cited by 11 publications

References 23 publications

Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis

Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis

Preclinical ⁸⁹Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis

International Federation of Gynecology and Obstetrics Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Estimation of Survival in Patients With Node-Positive Epithelial Ovarian Cancer

Contact Info

Product

Resources

About

The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer

Cited by 11 publications

References 23 publications

Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis

Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis

Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis

International Federation of Gynecology and Obstetrics Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Estimation of Survival in Patients With Node-Positive Epithelial Ovarian Cancer

Contact Info

Product

Resources

About

Preclinical ⁸⁹Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis